Impact of transdermal oxybutynin on depression symptoms in patients with overactive bladder - Results of the MATRIX study

被引：3
|
作者：
Sand, Peter K. [1 ]
Lucente, Vincent R. [1 ]
Parker, Robert Lamar [1 ]
Goldberg, Roger P. [1 ]
Dahl, Naomi V. [1 ]
机构：
[1] Northwestern Univ, Evanston, IL USA
来源：
OBSTETRICS AND GYNECOLOGY | 2006年 / 107卷 / 04期
关键词：
D O I：
10.1097/00006250-200604001-00182
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：76S / 76S
页数：1
相关论文
共 50 条
  • [1] Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder -: Results from MATRIX study
    Willy Davila, G.
    Sand, Peter K.
    Gonick, Charles W.
    Parker, Robert Lamar
    Dahl, Naomi V.
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 76S - 76S
  • [2] Impact of transdermal oxybutynin on quality of life in patients with overactive bladder - Results from the MATRIX study
    Lucente, Vincent R.
    Goldberg, Roger P.
    Davila, Willy
    Gonick, Charles W.
    Parker, Robert Lamar
    Dahl, Naomi V.
    OBSTETRICS AND GYNECOLOGY, 2006, 107 (04): : 74S - 75S
  • [3] Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive Bladder Results from the MATRIX Study
    Pizzi, Laura T.
    Talati, Amy
    Gemmen, Eric
    Dahl, Naomi V.
    Bunz, Thomas J.
    Sand, Peter K.
    PHARMACOECONOMICS, 2009, 27 (04) : 329 - 339
  • [4] Erratum to Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study
    Laura T. Pizzi
    Amy Talati
    Eric Gemmen
    Naomi V. Dahl
    Thomas J. Bunz
    Peter K. Sand
    PharmacoEconomics, 2012, 30 : 534 - 535
  • [5] Safety of transdermal oxybutynin in the treatment of overactive bladder among patients using other transdermal medications: Results of the matrix study.
    Pizzi, L. T.
    McIlwain, M.
    Dahl, N. V.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S105 - S105
  • [6] Transdermal oxybutynin for overactive bladder
    Davila, G. Willy
    Starkman, Jonathan S.
    Dmochowski, Roger R.
    UROLOGIC CLINICS OF NORTH AMERICA, 2006, 33 (04) : 455 - +
  • [7] Transdermal oxybutynin - For overactive bladder
    Bang, LM
    Easthope, SE
    Perry, CM
    DRUGS & AGING, 2003, 20 (11) : 857 - 864
  • [8] Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study (vol 27, pg 329, 2009)
    Pizzi, L. T.
    Talati, A.
    Gemmen, E.
    Dahl, N., V
    Bunz, T. J.
    Sand, P. K.
    PHARMACOECONOMICS, 2012, 30 (06) : 534 - 535
  • [9] Impact of Transdermal Oxybutynin on Work Productivity in Patients with Overactive BladderResults from the MATRIX Study
    Laura T. Pizzi
    Amy Talati
    Eric Gemmen
    Naomi V. Dahl
    Thomas J. Bunz
    Peter K. Sand
    PharmacoEconomics, 2009, 27 : 329 - 339
  • [10] Transdermal oxybutynin in the treatment of overactive bladder
    Davila, G. Willy
    CLINICAL INTERVENTIONS IN AGING, 2006, 1 (02) : 99 - 105
12345